Non-Small Cell Lung Cancer Clinical Trial
Official title:
An Open Label, Randomized, Phase I/II Study of DMXAA in Combination With Carboplatin and Paclitaxel in Patients With Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Verified date | January 2009 |
Source | Antisoma Research |
Contact | n/a |
Is FDA regulated | No |
Health authority | New Zealand: Medsafe |
Study type | Interventional |
This study was designed to test the addition of DMXAA (now known as ASA404) to carboplatin and paclitaxel in patients with NSCLC.
Status | Completed |
Enrollment | 105 |
Est. completion date | August 2007 |
Est. primary completion date | August 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: 1. Histologically confirmed non-small cell lung carcinoma designated as adenocarcinoma (including bronchoalveolar), squamous cell carcinoma or undifferentiated, mixed (adenocarcinoma and squamous) or large cell carcinoma. 2. Locally advanced Stage IIIb disease, not curable with surgery or radiotherapy, or Stage IV disease. 3. Aged = 18 years of age. 4. Karnofsky performance status of = 70%. 5. Life expectancy of = 3 months. 6. Hematological and biochemical indices at screening comprising: - An absolute neutrophil count of = 2.0 x 109/L. - A platelet count of = 100 x 109/L. - A hemoglobin level of = 10 g/dL. - Adequate hepatic and renal function as defined by serum bilirubin = 25 µmol/L; alkaline phosphatase, alanine transaminase (ALT) and aspartate transaminase (AST) = 2.5 times the upper limit of normal if no demonstrable liver metastasis or = 5 times the upper limit of normal in the presence of liver metastasis; serum creatinine = 120 µmol/L. 7. At least one unidimensionally measurable lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST). 8. Providing written informed consent and be able to comply with study assessments and follow-up. EXCLUSION CRITERIA: 1. Patients who had undergone major surgery, chemotherapy or radiation therapy (except palliative) within the previous 4 weeks. 2. A known history of hypersensitivity to carboplatin, paclitaxel or any of their excipients. 3. Previous exposure to DMXAA or other vascular targeting agents. 4. Small cell lung cancer or mixed histology. 5. Having received blood transfusions or growth factors to aid haematological recovery within 2 weeks of the scheduled baseline visit. 6. Active serious infection within 2 weeks of screening. 7. Clinically significant cardiac arrhythmias and known QTc prolongation. 8. Evidence of severe or uncontrolled systemic disease that might interfere with study participation. 9. A history of alcoholism, drug addiction or any psychiatric condition that would impair the patient's ability to comply with study procedures. 10. Pregnant or lactating women and women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test. 11. Patients should not have received within the two weeks prior to starting the study or be expected to need during the study period medications known to affect the QT interval or systemic serotonin levels. 12. Concurrent or previous malignancy of a different tumor type within 5 years of starting the study, except for adequately treated non-melanoma skin cancer or cervical intraepithelial neoplasia. 13. Clinical or radiological evidence of central nervous system metastases. 14. Evidence of any other clinically significant disorder or laboratory finding that might compromise patient safety. 15. Participation in any investigational drug study in which the study drug did not subsequently obtain a product license. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Antisoma Research |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and tolerability of combination | |||
Primary | Tumor response rate | |||
Primary | Time to tumor progression | |||
Primary | Duration of response and stable disease; median and one-year survival |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |